Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 4/20 | 0.47 |
| ▸ | RARB | P10826 | 3/20 | 0.47 |
| ▸ | RARG | P13631 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | GOT1 | P17174 | 1/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9077071 | 0.90 | RARB (0.63) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL7759671 | 0.89 | RARG (0.53) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL7927645 | 0.83 | RARB (0.54) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL566278 | 0.82 | RARA (0.62) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL8765831 | 0.79 | RARG (0.70) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL8691391 | 0.77 | RARA (0.54) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL2313836 | 0.76 | PDK2 (0.38) | RARARARBRARGMEN1LMNA | |
| SCHEMBL9078825 | 0.76 | RARB (0.52) | RARARARBRARGMEN1NR1I2 | |
| SCHEMBL2934710 | 0.76 | MAPT (0.57) | MEN1LMNAKMT2APKMMAPT | |
| SCHEMBL14616750 | 0.76 | NOTUM (0.53) | LMNAKMT2ATDP1PKMSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992095-B2 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-04-08 | — | — | US | disclosed |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | BERNARDON JEAN-MICHEL (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6214878-B1 | SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2001-04-10 | — | — | US | disclosed |
| US-5468897-A | Bi-aromatic esters, a process for their preparation and their use in human or veterinary medicine and in cosmetic compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-11-21 | — | — | US | disclosed |
| US-5332856-A | Treatment of a dermatologic, rheumatismal, respiratory or ophthalmologic ailment | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1994-07-26 | — | — | US | disclosed |
| US-5200550-A | Administering for dermatologic, rheumatismal, respiratory or ophthalomologic disorders | CENTRE INTERNATIONAL DE RECHERCES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1993-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RARA 1151/4885RARB 406/4885RARG 1564/4885 |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RARA 1151/4885RARB 406/4885RARG 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.